Tripartite Computational Alliance and $237 Million Funding Round
International biopharmaceutical markets welcomed a decisive convergence of data science and neuroscience on Friday as Pathos AI formally partnered with Bristol Myers Squibb and Tempus AI. The collaborative initiative is engineered to deploy machine learning architectures against historical biological hurdles in Alzheimer's disease and kindred neurodegenerative pathologies.
In conjunction with the scientific agreement, Pathos completed a $237 million Series E funding round led directly by Bristol Myers Squibb, supported by substantial reinvestment from legacy venture shareholders. The capital injection formalizes a post-money market valuation of approximately $3 billion for the New York-headquartered company, demonstrating institutional conviction in AI-directed therapeutic discovery.
Pathos AI entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease.

















